{"pmid":32319301,"title":"COVID-19: How has the scientific community risen to the challenge?","text":["COVID-19: How has the scientific community risen to the challenge?","As the novel coronavirus SARS-CoV-2 spreads around the world, scientists have raced to develop vaccines and tests in order to curb the infection.","Biotechniques","Straiton, Jenny","32319301"],"abstract":["As the novel coronavirus SARS-CoV-2 spreads around the world, scientists have raced to develop vaccines and tests in order to curb the infection."],"journal":"Biotechniques","authors":["Straiton, Jenny"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319301","week":"202017|Apr 20 - Apr 26","doi":"10.2144/btn-2020-0041","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1664815087623340032,"score":8.518259,"similar":[{"pmid":32205349,"title":"Updated approaches against SARS-CoV-2.","text":["Updated approaches against SARS-CoV-2.","The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in the virology, epidemiology and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing towards the development of treatment for COVID-19. Recent studies have revealed many attractive threptic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials. In this minireview, we aim to summarize the updated potential approaches against SARS-CoV-2. We emphasize that further efforts are warranted to develop the safest and most effective approach.","Antimicrob Agents Chemother","Li, Haiou","Zhou, Yunjiao","Zhang, Meng","Wang, Haizhou","Zhao, Qiu","Liu, Jing","32205349"],"abstract":["The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in the virology, epidemiology and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing towards the development of treatment for COVID-19. Recent studies have revealed many attractive threptic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials. In this minireview, we aim to summarize the updated potential approaches against SARS-CoV-2. We emphasize that further efforts are warranted to develop the safest and most effective approach."],"journal":"Antimicrob Agents Chemother","authors":["Li, Haiou","Zhou, Yunjiao","Zhang, Meng","Wang, Haizhou","Zhao, Qiu","Liu, Jing"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205349","week":"202013|Mar 23 - Mar 29","doi":"10.1128/AAC.00483-20","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352133685084162,"score":92.72814},{"pmid":32209598,"title":"COVID-19 Challenges Basic Researchers.","text":["COVID-19 Challenges Basic Researchers.","As COVID-19 continues to surge, cancer scientists engaged in basic research face unique challenges. At centers throughout the United States, investigators are confronting difficult decisions about which experiments to continue, while securing supplies and creating contingency plans for a complete shutdown.","Cancer Discov","32209598"],"abstract":["As COVID-19 continues to surge, cancer scientists engaged in basic research face unique challenges. At centers throughout the United States, investigators are confronting difficult decisions about which experiments to continue, while securing supplies and creating contingency plans for a complete shutdown."],"journal":"Cancer Discov","date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209598","week":"202013|Mar 23 - Mar 29","doi":"10.1158/2159-8290.CD-NB2020-018","source":"PubMed","topics":["General Info"],"weight":1,"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664638933397405696,"score":76.34745},{"pmid":31979013,"pmcid":"PMC7077218","title":"Emerging Viruses without Borders: The Wuhan Coronavirus.","text":["Emerging Viruses without Borders: The Wuhan Coronavirus.","The recently emerged coronavirus in Wuhan, China has claimed at least two lives as of January 17 and infected hundreds if not thousands of individuals. The situation has drawn international attention, including from the virology community. We applaud the rapid release to the public of the genome sequence of the new virus by Chinese virologists, but we also believe that increased transparency on disease reporting and data sharing with international colleagues are crucial for curbing the spread of this newly emerging virus to other parts of the world.","Viruses","Liu, Shan-Lu","Saif, Linda","31979013"],"abstract":["The recently emerged coronavirus in Wuhan, China has claimed at least two lives as of January 17 and infected hundreds if not thousands of individuals. The situation has drawn international attention, including from the virology community. We applaud the rapid release to the public of the genome sequence of the new virus by Chinese virologists, but we also believe that increased transparency on disease reporting and data sharing with international colleagues are crucial for curbing the spread of this newly emerging virus to other parts of the world."],"journal":"Viruses","authors":["Liu, Shan-Lu","Saif, Linda"],"date":"2020-01-26T11:00:00Z","year":2020,"_id":"31979013","week":"20204|Jan 20 - Jan 26","doi":"10.3390/v12020130","source":"PubMed","topics":["General Info"],"weight":1,"locations":["Wuhan","China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875422023681,"score":74.21384},{"pmid":32234130,"title":"[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","text":["[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.","Zhonghua Yu Fang Yi Xue Za Zhi","Shi, Y","Wang, N","Zou, Q M","32234130"],"abstract":["The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated."],"journal":"Zhonghua Yu Fang Yi Xue Za Zhi","authors":["Shi, Y","Wang, N","Zou, Q M"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234130","week":"202014|Mar 30 - Apr 05","doi":"10.3760/cma.j.cn112150-20200317-00366","keywords":["2019-ncov","animal models","vaccine"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Moderna"],"_version_":1664638354136760320,"score":69.96268},{"pmid":32023682,"title":"[2019-nCoV: new challenges from coronavirus].","text":["[2019-nCoV: new challenges from coronavirus].","The outbreak of pneumonia caused by the novel coronavirus 2019-nCoV in Wuhan, Hubei province of China, at the end of 2019 shaped tremendous challenges to China's public health and clinical treatment. The virus belongs to the beta genus Coronavirus in the family Corornaviridae, and is closely related to SARS-CoV and MERS-CoV, causing severe symptoms of pneumonia. The virus is transmitted through droplets, close contact, and other means, and patients in the incubation period could potentially transmit the virus to other persons. According to current observations, 2019-nCoV is weaker than SARS in pathogenesis, but has stronger transmission competence; it's mechanism of cross-species spread might be related with angiotensin-converting enzyme (ACE2), which is consistent with the receptor SARS-CoV. After the outbreak of this disease, Chinese scientists invested a lot of energy to carry out research by developing rapid diagnostic reagents, identifying the characters of the pathogen, screening out clinical drugs that may inhibit the virus, and are rapidly developing vaccines. The emergence of 2019-nCoV reminds us once again of the importance of establishing a systematic coronavirus surveillance network. It also poses new challenges to prevention and control of the emerging epidemic and rapidly responses on scientific research.","Zhonghua Yu Fang Yi Xue Za Zhi","Tian, H Y","32023682"],"abstract":["The outbreak of pneumonia caused by the novel coronavirus 2019-nCoV in Wuhan, Hubei province of China, at the end of 2019 shaped tremendous challenges to China's public health and clinical treatment. The virus belongs to the beta genus Coronavirus in the family Corornaviridae, and is closely related to SARS-CoV and MERS-CoV, causing severe symptoms of pneumonia. The virus is transmitted through droplets, close contact, and other means, and patients in the incubation period could potentially transmit the virus to other persons. According to current observations, 2019-nCoV is weaker than SARS in pathogenesis, but has stronger transmission competence; it's mechanism of cross-species spread might be related with angiotensin-converting enzyme (ACE2), which is consistent with the receptor SARS-CoV. After the outbreak of this disease, Chinese scientists invested a lot of energy to carry out research by developing rapid diagnostic reagents, identifying the characters of the pathogen, screening out clinical drugs that may inhibit the virus, and are rapidly developing vaccines. The emergence of 2019-nCoV reminds us once again of the importance of establishing a systematic coronavirus surveillance network. It also poses new challenges to prevention and control of the emerging epidemic and rapidly responses on scientific research."],"journal":"Zhonghua Yu Fang Yi Xue Za Zhi","authors":["Tian, H Y"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32023682","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.0253-9624.2020.0001","keywords":["2019-ncov","coronavirus","public health"],"source":"PubMed","topics":["Mechanism","Prevention","Transmission","Treatment"],"weight":1,"locations":["Wuhan","Hubei","China","China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875369594881,"score":66.227455}]}